Persones / Equip Humà

Jaume Mora Graupera

Buscador de publicacions

Publicacions

  • Mahnoor S, Molnar C, Velázquez D, Reina J, Llamazares S, Heinen JP, Mora J and Gonzalez C.

    Human EWS-FLI protein levels and neomorphic functions show a complex, function-specific dose-response relationship in Drosophila.

    OPEN BIOLOGY . 14(7): 240043-240043.

    [doi:10.1098/rsob.240043]

  • Caballero R, Pasten A, Giménez C, Raquel Rodriguez Baladon, Carmona-Jiménez RM, Mora J, Valls-Esteve A, Lustig P, Lombardini F, Balsells S and Krauel L.

    Beyond Needles: Pioneering Pediatric Care with Virtual Reality (VR) for TIVAD Access in Oncology.

    Cancers . 16(12): .

    [doi:10.3390/cancers16122187]

  • Sanchez-Guixe E, Muiños F, Pinheiro-Santin M, González-Huici V, Rodriguez-Hernandez CJ, Avgustinova A, Lavarino C, González- Pérez A, Mora J and López-Bigas N.

    Origins of Second Malignancies in Children and Mutational Footprint of Chemotherapy in Normal Tissues

    CANCER DISCOVERY . 14(6): 953-964. Nº de cites: 2

    [doi:10.1158/2159-8290.CD-23-1186]

  • Mora J, Climent A, Roldan-Molina M, Flores MC, Varo A, Pérez-Jaume S, Jou-Munoz C, Celma MS, Lazaro JJ, Cheung I, Castañeda-Heredia A, Gorostegui M, Rodriguez E, Chamorro S, Muñoz JP and Cheung NK.

    Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects.

    Frontiers in oncology . 14: 1380917-1380917.

    [doi:10.3389/fonc.2024.1380917]

  • Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J.

    Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy

    Cancers . 16(9): .

    [doi:10.3390/cancers16091735]

  • Pasten A, Salvador-Alarcon C, Mora J, Martín Gimenez MP, Carrasco-Torrents R and Krauel L.

    Current Status of Fertility Preservation in Pediatric Oncology Patients.

    CHILDREN-BASEL . 11(5): .

    [doi:10.3390/children11050537]

  • Mora J, Modak S, Kinsey J, Ragsdale CE and Lazarus HM.

    GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma

    INTERNATIONAL JOURNAL OF CANCER . 154(8): 1340-1364. Nº de cites: 3

    [doi:10.1002/ijc.34815]

  • Llurba E, Fàtima Crispi Brillas, Crovetto F, Youssef L, Delgado JL, Puig I, Mora J, Krofta L, Mackova K, Martinez-Varea A, Tubau A, Ruiz-Llobet A, Paya A, Prat M, Chantraine F, Comas C, Kajdy A, Lopez-Tinajero MF, Figueras-Retuerta F and Gratacós E.

    Multicentre randomised trial of screening with sFlt1/PlGF and planned delivery to prevent pre-eclampsia at term: protocol of the PE37 study.

    BMJ Open . 14(3): . Nº de cites: 1

    [doi:10.1136/bmjopen-2023-076201]

  • Villasante A, Corominas J, Alcon C, Garcia-Lizarribar A, Mora J, Lopez-Fanarraga M and Samitier J.

    Identification of GB3 as a Novel Biomarker of Tumor-Derived Vasculature in Neuroblastoma Using a Stiffness-Based Model

    Cancers . 16(5): .

    [doi:10.3390/cancers16051060]

  • Aschero MR, Ganiewich D, Lamas G, Restrepo-Perdomo CA, Ottaviani D, Zugbi S, Camarero S, Néspoli E, Cuadrado-Vilanova M, Pérez-Jaume S, Pascual-Pastó G, Sampor C, Grigorovski N, Salas B, Suñol M, Carcaboso AM, Mora J, de Dávila MTG, Doz F, Radvanyi F, Abramson DH, Llera AS, Schaiquevich PS, Lubieniecki F and Chantada G.

    Immunohistochemical expression of TFF1 is a marker of poor prognosis in retinoblastoma

    PEDIATRIC BLOOD & CANCER . 71(1): . Nº de cites: 1

    [doi:10.1002/pbc.30717]